In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450

Drug Metabolism and Disposition

Volumn 30, Issue 7, 2002, Pages 805-813

  Zhang, Zhi Yi ^a   King, Belinda M ^b   Mollova, Nevena N ^a   Nancy Wong, Y ^b  

^a EISAI RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; E 2101; MUSCLE RELAXANT AGENT; N METHYL [1 [1 (2 FLUOROPHENETHYL)PIPERIDIN 4 YL] 1H INDOL 6 YL]ACETAMIDE; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; CENTRAL MUSCLE RELAXANT; ENZYME INHIBITOR; ISOENZYME; PIPERIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL CULTURE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPASTICITY; STATISTICAL ANALYSIS; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; ENZYME INDUCTION; ENZYMOLOGY; LIVER MICROSOME; METABOLISM;

ACETAMIDES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ENZYME INHIBITORS; HUMAN; ISOENZYMES; MICROSOMES, LIVER; MUSCLE RELAXANTS, CENTRAL; PIPERIDINES; SEROTONIN ANTAGONISTS; HUMANS;

EID: 0035987893     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.7.805     Document Type: Article

References (42)

1. Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1′-hydroxylase activities
2. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
3. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae
4. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species
5. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine
6. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
7. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites
8. Pattern of Enzyme Inhibition
9. Metabolism, pharmacogenetics and metabolic drug-drug interactions of antipsychotic drugs
10. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to MI mutation of CYP2C19 and gene dose
11. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants
12. Induction of CYP2C genes in human hepatocytes in primary culture
13. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
14. Role of 5-HT in stress, anxiety and depression
15. Overview of the pharmacokinetics of fluvoxamine
16. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part II
17. Serotonin autoreceptor function and antidepressant drug action
18. Novel mutations of CYP3A4 in Chinese
19. i in a competitive enzyme-inhibition model: Comparisons among three methods of data analysis
20. Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo
21. Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYP1A1 or CYP1A2
22. Investigation of substrate structure activity relationships (SSAR) for cytochrome P4502C19
23. Drug interactions of HIV protease inhibitors
24. Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: Involvement of CYP3A4 characterized by atypical kinetics with two binding sites
25. Diverse signalling by 5-hydroxytryptamine (5-HT) receptors
26. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions
27. Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs
28. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia
29. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
30. Serotonin receptors: Subtypes, functional responses and therapeutic relevance
31. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
32. Enzyme kinetics of cytochrome P450-mediated reactions
33. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain
34. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates
35. Interactions between cyclosporine and newer antidepressant medications
36. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance
37. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent
38. Studies on the 4-hydroxycoumarins. XVII. The resolution and absolute configuration of warfarin
39. 2,3,7,8 Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes
40. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19
41. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe